Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISE
2024-510770-25-00Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Adjunctive KarXT with Adjunctive Placebo (2 arms). Primary endpoint: Change from Baseline in PANSS total score at Week 6. Started Jun 2024; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-510770-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510770-25-00.